Importer of Controlled Substances; Notice of Registration, 38209 [2011-16286]
Download as PDF
Federal Register / Vol. 76, No. 125 / Wednesday, June 29, 2011 / Notices
Vernon County
Vernon County Normal School, 410 S. Center
Ave., Viroqua, 11000479
& Clinton St. between 6th & 9th Sts.,
Arkadelphia, 11000464
COLORADO
Arapahoe County
[FR Doc. 2011–16248 Filed 6–28–11; 8:45 am]
Englewood Post Office, 3332 S. Broadway,
Englewood, 11000465
BILLING CODE 4312–51–P
DISTRICT OF COLUMBIA
DEPARTMENT OF JUSTICE
District of Columbia
Drug Enforcement Administration
Linnaean Hill (Boundary Increase), 3545
Williamsburg Ln., NW., Washington,
11000466
Manufacturer of Controlled
Substances; Notice of Application
MINNESOTA
Fillmore County
Bridge No. 5722, N. Section St. over Spring
Valley Cr., Spring Valley, 11000467
Houston County
Bridge No. 6679, MN 76 over S. Fork of Root
R. (Sheldon Township), Houston,
11000468
Swift County
Gethsemane Episcopal Church, 40 N. Hering
St., Appleton, 11000469
Traverse County
District No. 44 School, U.S. 75 (Taylor
Township), Campbell, 11000470
MISSISSIPPI
Lee County
Baldwyn Historic District, Roughly along E.
& W. Main Sts. & N. & S. 2nd Ave.,
Baldwyn, 11000471
Webster County
Eupora Historic District, Roughly along N.
Dunn St. & W. Roane Ave., Eupora,
11000472
Winston County
Downtown Louisville Historic District,
Bounded by Church St., W. Park St.,
Columbus Ave. & Mill St., Louisville,
11000473
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 14, 2011,
Pharmagra Labs, Inc., 158 McLean Road,
Brevard, North Carolina 28712, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Pentobarbital
(2270), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed substances for analytical
research and clinical trials.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 29, 2011.
Dated: June 22, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Yazoo County
Dated: June 22, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–16286 Filed 6–28–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
BILLING CODE 4410–09–P
NEW MEXICO
[OJP; BJA Docket No. 1561]
McKinley County
Borrego Pass Trading Post Historic District,
Bldg. 1601, Co. Rd. 19, Borrego Pass,
11000475
WASHINGTON
Whatcom County
Lynden Department Store, 444 Front St.,
Lynden, 11000476
mstockstill on DSK4VPTVN1PROD with NOTICES
drug product in dosage form only for
distribution to its customers. The
company does not import the listed
controlled substance in bulk active
pharmaceutical ingredient (API) form.
There are no domestic sources of
Nabilone in finished drug product form
available in the United States. The U.S.
Food and Drug Administration has
approved this product for medical use
in the United States.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a),
and determined that the registration of
Meda Pharmaceuticals Inc. to import the
basic class of controlled substance is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Meda Pharmaceuticals
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
[FR Doc. 2011–16294 Filed 6–28–11; 8:45 am]
Rosedale Plantation, 5302 Bend Rd.,
Vaughan, 11000474
WISCONSIN
Rock County
Eager, Almeron, Funerary Monument and
Plot, 8012 N. Cemetery Rd., Evansville,
11000477
Sauk County
Rest Haven Motel, E5116 U.S. 14, Spring
Green, 11000478
VerDate Mar<15>2010
38209
17:48 Jun 28, 2011
Jkt 223001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 11, 2011, and
published in the Federal Register on
April 19, 2011, 76 FR 21915, Meda
Pharmaceuticals, Inc., 705 Eldorado
Street, Decatur, Illinois 62523, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance as a finished
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
Meeting of the Department of Justice’s
(DOJ’s) National Motor Vehicle Title
Information System (NMVTIS) Federal
Advisory Committee
Bureau of Justice Assistance,
Justice.
ACTION: Notice of meeting.
AGENCY:
This is an announcement of a
meeting of DOJ’s National Motor
Vehicle Title Information System
(NMVTIS) Federal Advisory Committee
to discuss the role of the NMVTIS
Federal Advisory Committee Members
and various issues relating to the
operation and implementation of
NMVTIS.
SUMMARY:
E:\FR\FM\29JNN1.SGM
29JNN1
Agencies
[Federal Register Volume 76, Number 125 (Wednesday, June 29, 2011)]
[Notices]
[Page 38209]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-16286]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated April 11, 2011, and published in the Federal
Register on April 19, 2011, 76 FR 21915, Meda Pharmaceuticals, Inc.,
705 Eldorado Street, Decatur, Illinois 62523, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of Nabilone (7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the listed controlled substance as a
finished drug product in dosage form only for distribution to its
customers. The company does not import the listed controlled substance
in bulk active pharmaceutical ingredient (API) form.
There are no domestic sources of Nabilone in finished drug product
form available in the United States. The U.S. Food and Drug
Administration has approved this product for medical use in the United
States.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and Sec. 952(a), and determined that
the registration of Meda Pharmaceuticals Inc. to import the basic class
of controlled substance is consistent with the public interest, and
with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971. DEA has
investigated Meda Pharmaceuticals Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer
of the basic class of controlled substance listed.
Dated: June 22, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-16286 Filed 6-28-11; 8:45 am]
BILLING CODE 4410-09-P